StockNews.com Begins Coverage on Oragenics (NYSE:OGEN)

Stock analysts at StockNews.com started coverage on shares of Oragenics (NYSE:OGEN) in a report released on Wednesday. The firm set a “sell” rating on the stock.

Oragenics Stock Performance

NYSE:OGEN opened at $0.30 on Wednesday. The firm has a market cap of $3.62 million, a P/E ratio of -0.04 and a beta of 0.40. Oragenics has a fifty-two week low of $0.25 and a fifty-two week high of $6.22. The firm has a 50-day simple moving average of $0.34 and a two-hundred day simple moving average of $0.63.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.